Combination of the PARP inhibitor olaparib with the vascular disrupting agent NOV202 reduces tumor growth in BRCA1/2 mutated prostate cancer xenografts

Bibliographic Details
Main Authors:	A.S. Bjartell, E. Sereti, S. Evans Axelsson
Format:	Article
Language:	English
Published:	Elsevier 2023-02-01
Series:	European Urology Open Science
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666168323000459

Internet